Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Binimetinib + Encorafenib & Melanoma (cutaneous) (BRAF m), Binimetinib + Encorafenib is approved by both the FDA and the EMA for Melanoma (cutaneous) (BRAF m), but only in the unresectable or metastatic setting and specifically for BRAF V600‑mutant disease (2, 3).
The randomized clinical phase III treatment trial NCT01909453 (COLUMBUS) demonstrated that in a 5-year update of part 1 of the trial, Binimetinib + Encorafenib t…